Atrophic gastritis, caused by Helicobacter pylori infection or autoimmune diseases, can elevate the risk of gastric and esophageal cancers, along with impairing the absorption of vitamin B12, calcium, iron, zinc, and magnesium. Now, a rapid test allows for fast diagnosis of and screening for Helicobacter pylori, atrophic gastritis with related risks, and elevated stomach acid output in both symptomatic and asymptomatic patients.

BIOHIT HealthCare (Helsinki, Finland) is rolling out its innovative GastroPanel Quick Test - a revolutionary approach to the diagnosis of Helicobacter pylori infection, atrophic gastritis, and high acid outputs in symptomatic as well as asymptomatic patients. The GastroPanel Quick Test is an advanced version of the unique Biohit GastroPanel examination. This rapid, non-invasive test investigates Helicobacter pylori infection and three stomach-specific biomarkers – pepsinogen I, pepsinogen II, and gastrin-17 – within just 15 minutes. This tool can assist clinicians in expediting patient referrals for endoscopy at a lower cost, which may result in earlier cancer detection and interventions via surveillance programs.

The GastroPanel Quick Test utilizes the immunoassay method to identify GastroPanel biomarkers from EDTA plasma, enabling the first-line diagnosis of dyspeptic patients and screening of symptomatic and asymptomatic patients more conveniently than ever before. Besides reducing costs and eliminating needless clinical visits, the GastroPanel Quick Test considerably enhances patient safety, as it accelerates referrals for further examinations, treatments, and follow-ups. 

http://www.gzjiayumed.com/en/index.asp